Revolution Medicines, Inc. (RVMD) Stock Score, Valuation & Financial Research

Revolution Medicines, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RVMD

Revolution Medicines, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 209.41. These figures are a research snapshot, not a buy or sell recommendation.

What Revolution Medicines, Inc. does

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Revolution Medicines is a clinical-stage precision oncology company that does not yet generate commercial product revenue. It funds its research and development activities primarily through equity financing, collaborations, and licensing agreements, aiming to monetize its proprietary RAS(ON) inhibitor platform through future regulatory approvals and commercialization of targeted cancer therapies.

Products and services

  • The company is developing a pipeline of targeted oncology therapies, specifically RAS(ON) inhibitors such as zoldonrasib and daraxonrasib, designed to treat patients with RAS-addicted cancers.

Brands and product families

  • Zoldonrasib — Lead G12D-selective RAS(ON) inhibitor candidate. Source
  • Daraxonrasib — RAS(ON) inhibitor candidate targeting multiple RAS isoforms. Source

Customer types

Clinical trial patients; Healthcare providers and oncology centers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of drug substances and drug products for clinical trials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Tango Therapeutics — A clinical collaboration evaluating Revolution Medicines’ RAS(ON) inhibitors in combination with vopimetostat, Tango’s MTA-cooperative PRMT5 inhibitor. Source

Competitors and product-market comparisons

  • Mirati Therapeutics (Bristol Myers Squibb) — Competes in the development of KRAS-targeted therapies. Source
  • Amgen — Competes in the development of KRAS-targeted therapies. Source

Business strengths to evaluate

  • Proprietary RAS(ON) inhibitor platform Source
  • Deep pipeline of targeted oncology candidates Source

Business risks and research considerations

  • History of operating losses and potential inability to achieve profitability Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Clinical trial failure or regulatory rejection Source

Sources: Company research source · Zoldonrasib

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RVMD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 209.41
Market capitalization:
44.52B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -1.77B
Free cash flow:
USD -913.73M
Cash:
USD 815.44M
Total debt:
USD 641.93M
EPS:
USD -8.86

What stands out

  • Free cash flow is USD -913.73M, negative for the stored period.
  • The balance sheet shows USD 815.44M of cash versus USD 641.93M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 173.51M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RVMD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can RVMD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does RVMD's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for RVMD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of RVMD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research RVMD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.